2509 — Qyuns Therapeutics Co Income Statement
0.000.00%
Last trade - 00:00- HK$6.02bn
- HK$5.99bn
Annual income statement for Qyuns Therapeutics Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 169 | 294 | 505 |
| Operating Profit | -169 | -294 | -505 |
| Total Net Non Operating Interest Income / Expense | |||
| Net Income Before Taxes | -427 | -312 | -521 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -426 | -312 | -521 |
| Minority Interest | |||
| Net Income Before Extraordinary Items | |||
| Net Income | -411 | -298 | -508 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -411 | -298 | -508 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -1.82 | -1.31 | -2.22 |